Cullen Frost Bankers Inc. Has $25.70 Million Stock Position in Danaher Corporation $DHR

Cullen Frost Bankers Inc. lowered its holdings in shares of Danaher Corporation (NYSE:DHR) by 3.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 130,114 shares of the conglomerate’s stock after selling 4,106 shares during the period. Cullen Frost Bankers Inc.’s holdings in Danaher were worth $25,703,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of DHR. GAMMA Investing LLC lifted its holdings in shares of Danaher by 22.2% during the first quarter. GAMMA Investing LLC now owns 9,126 shares of the conglomerate’s stock valued at $1,871,000 after acquiring an additional 1,660 shares during the period. Pacific Capital Partners Ltd acquired a new position in shares of Danaher during the 1st quarter worth about $7,175,000. Flagship Harbor Advisors LLC grew its position in shares of Danaher by 13.7% during the 1st quarter. Flagship Harbor Advisors LLC now owns 10,149 shares of the conglomerate’s stock worth $2,081,000 after buying an additional 1,221 shares during the period. Oppenheimer & Co. Inc. grew its position in shares of Danaher by 9.2% during the 1st quarter. Oppenheimer & Co. Inc. now owns 25,096 shares of the conglomerate’s stock worth $5,145,000 after buying an additional 2,122 shares during the period. Finally, Valmark Advisers Inc. grew its position in shares of Danaher by 3.4% during the 1st quarter. Valmark Advisers Inc. now owns 2,365 shares of the conglomerate’s stock worth $485,000 after buying an additional 78 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insiders Place Their Bets

In related news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 11.20% of the company’s stock.

Danaher Trading Up 6.1%

Shares of Danaher stock opened at $221.13 on Wednesday. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $269.24. The stock has a market cap of $158.34 billion, a P/E ratio of 47.05, a P/E/G ratio of 3.01 and a beta of 0.77. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average is $202.07 and its 200-day moving average is $197.59.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the prior year, the business earned $1.71 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio is 27.23%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Wells Fargo & Company decreased their price objective on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 23rd. UBS Group decreased their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, July 23rd. Scotiabank raised Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Finally, Redburn Partners set a $220.00 price target on Danaher in a research note on Wednesday, October 8th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.